alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › What the research found › Every row

Every row of the evidence table

One row per finding: what was tested, which way the result went, and how the study was built. The answer by area, and where the studies disagree, are on the main page.

Every row

Filter

Area All 382 Care, carers and services 140 Medicines 85 Genes (not modifiable) 35 All modifiable factors together 27 Diet and supplements 23 Exercise and activity 21 Sleep, mood and social life 19 Hearing and vision 8 Alcohol, tobacco and cannabis 6 Infection and vaccination 5 Heart and metabolic health 4 Injury, delirium and falls 4 Environment 3 Cognitive activity 2
Question Both Prevention 190 Treatment 192
Direction Any Benefit 144 Harm 105 No effect 38 Mixed 37 No direction reported 58
Design Any meta-analysis 57 randomised trial 44 phase 3 trial 15 systematic review 9 phase 2 trial 10 cohort study 136 phase 1 trial 2 cross-sectional study 31 case-control study 14 modelling study 20 regulatory decision 7 company announcement 1 coverage determination 1 None 35
Clear all

Showing 2 of 382 rows. One row per study per exposure: a study that tested two different things appears twice, once for each.

Scroll the table sideways to see every column.

Research and outcomes, 2 rows. Every row links to its source.
Exposure Question Direction Outcome measured Design People Effect size, as the source reported it Source
Cost-effectiveness of multidomain prevention programme Care, carers and services Prevention Mixed
why

Direction is for value for money: APPLE-Tree had a 96% probability of being cost-effective per cognition point at a £30 000 threshold but only 12% on QALYs, which were slightly lower in the intervention arm. Post hoc subgroups suggested better value in non-White and socioeconomically disadvantaged participants.

 QALYs over 24 months (primary) and cost per 1-point NTB cognition gain randomised trial 746 Mean adjusted QALYs were 1.511 (intervention) and 1.520 (control), an adjusted difference of -0.010 (95%CI -0.04 to -0.022). Mean adjusted (SD) costs were £2966 (3629) and £2551 (4439), respectively. Cost per 1-point NTB change z-score was £6809. At a £30 000 threshold, the probability of cost-effective was 12% and 96% based on QALYs and cognition, respectively Age and ageing 2026
✓ Peer-reviewed PMID 42328805
Dementia care management / navigation Care, carers and services Treatment Mixed
why

The two perspectives disagree: the digitally supported care management system dominated usual care for the public payer (lower costs, marginally more QALYs, 72-79% probability of cost-effectiveness) but cost €331,000 per QALY from a societal perspective (33-35% probability).

 Caregiver QALYs, costs and incremental cost per QALY at six months, from public-payer and societal perspectives randomised trial 192 Caregivers in the intervention group gained QALYs (+0.004 [95% CI -0.003 to 0.012], P value = .225) and had lower costs from the public payer (-378€ [1926-1168], P value = .630), but higher costs from the societal perspective (+1324 [-3634 to 6284], P value = .599). The intervention dominated usual care from the payer perspective, whereas the incremental cost-effectiveness ratio was €331 000/QALY from a societal perspective Value in Health 2025
✓ Peer-reviewed PMID 39922302

How this table was built, and where it is weak →